NASDAQ · BMGL
Basel Medical Group financials
$3.10−10.66%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jun 30 |
|---|---|
| Revenue | $8.9M |
| Gross profit | $8.9M |
| Gross margin | 100.0% |
| Operating income | -$1.8M |
| Net income | -$9.5M |
| Net margin | −106.8% |
| Diluted EPS | $-6.07 |
| EBITDA | -$1.7M |
| Operating cash flow | -$3.4M |
| Free cash flow | -$3.4M |
| Diluted shares | 1.6M |
Balance sheet
| Period end | Jun 30 |
|---|---|
| Cash & equivalents | $2.3M |
| Short-term investments | $0.00 |
| Total debt | $2.7M |
| Total assets | $13.3M |
| Total liabilities | $9.4M |
| Shareholders' equity | $3.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology